A Phase 3b, Open-label, Multicenter, Two-Period, Slow-titration and Food Effect Study to Assess the Safety and Efficacy of KarXT in Participants With DSM-5 Schizophrenia
Latest Information Update: 08 Apr 2025
At a glance
- Drugs Trospium chloride/xanomeline (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Karuna Therapeutics
Most Recent Events
- 02 Apr 2025 Status changed from active, no longer recruiting to completed.
- 06 Feb 2025 Status changed from recruiting to active, no longer recruiting.
- 17 Oct 2024 Status changed from not yet recruiting to recruiting.